Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Exosomes derived from TGF-β1-modified mesenchymal stem cells protect septic mice by inducing macrophage M2 polarization

Liu F., Liu L., Zhao X., Zhou F.

Animal Study on Chronic Inflammation, published in Mol Biol Rep (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Mol Biol Rep (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41880049
PMCID
PMC13017991
DOI
10.1007/s11033-026-11715-z

Abstract (original English)

Background Exosomes derived from mesenchymal stem cells (MSCs) have been reported to improve the prognosis in septic mice. Additionally, we have confirmed that TGF-β1 plays a critical role in MSC-mediated protection against sepsis. In this study, we aimed to investigate whether exosomes derived from TGF-β1-overexpressing MSCs (TGF-β1-Exo) offer protective effects in sepsis. Methods MSCs were collected from mouse MSCs stably transfected with TGF-β1 using a lentiviral vector. Exosomes were isolated and purified from MSCs (Exo), GFP-MSCs (GFP-Exo), and TGF-β1-MSCs (TGF-β1-Exo). A sepsis model was induced in mice via cecal ligation and perforation (CLP). After 6 h, exosomes from different sources were intravenously administered into septic mice. Mice were euthanised 24 h later, and histopathological changes were assessed using hematoxylin and eosin (H&E) staining. Inflammatory cytokine levels were measured using ELISA and RT-PCR. Flow cytometry was employed to evaluate macrophage phenotypes in lung tissues and in vitro macrophages. Additionally, we co-cultured fluorescently labeled exosomes with macrophages in vitro. Results TGF-β1-Exo significantly ameliorated histopathological damage and improved survival rates in septic mice. ELISA and RT-PCR analyses revealed that several pro-inflammatory cytokines were notably suppressed in the TGF-β1-Exo group. Furthermore, TGF-β1-Exo promote

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
MacrophagesMesenchymal Stem CellsAnimalsMice, Inbred C57BLMiceSepsisDisease Models, AnimalCytokinesMacrophage ActivationMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research